Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.57 |
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6253486 | 1.00 | CHRNB2 (0.57) | CHRNB2CHRNA4HRH1CYP2A6 | |
| SCHEMBL6254874 | 0.98 | CHRNB2 (0.59) | CHRNB2CHRNA4HRH1CYP2A6 | |
| SCHEMBL4805267 | 0.93 | CHRNB2 (0.61) | CHRNB2CHRNA4HRH1CYP2A6 | |
| SCHEMBL31483083 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL1622662 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL9367178 | 0.82 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL19055583 | 0.82 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL4944203 | 0.82 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL30542607 | 0.82 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL4888697 | 0.82 | CHRNB2 (0.62) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-7807682-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2010-10-05 | — | — | US | disclosed |
| EP-1397355-B1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2009-09-09 | — | — | EP | disclosed |
| EP-2096107-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1674457-B1 | Derivatives of squaric acid with anti-proliferative activity | GPC BIOTECH AG (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2008-04-17 | — | — | US | disclosed |
| US-7304066-B2 | Pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2007-12-04 | — | — | US | disclosed |
| EP-1674457-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2004-11-04 | — | — | US | disclosed |
| EP-1397355-A1 | PYRIDYL CYANOGUANIDINE COMPOUNDS | Leo Pharma A/S (DK) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094813-A1 | NOVEL PYRIDYL CYANOGUANIDINE COMPOUNDS | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220408-A1 | Novel pyridyl cyanoguanidine compounds | DAO, AOC1, SIGMAR1 | CHRNB2 1829/4885CHRNA4 1473/4885HRH1 365/4885 |
| US-20080090842-A1 | Novel pyridyl cyanoguanidine compounds | DAO, CCNY, CBR1 | CHRNB2 1463/4885CHRNA4 1435/4885HRH1 151/4885 |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | SQLE, FDFT1, DLD | CHRNB2 4467/4885CHRNA4 4613/4885HRH1 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.